Profile for Canada Patent: 2685127

US Patent Family Members and Approved Drugs for Canada Patent: 2685127

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,131,907	Aug 24, 2028	Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium
10,131,907	Aug 24, 2028	Alnylam Pharms Inc	GIVLAARI	givosiran sodium
10,131,907	Aug 24, 2028	Novartis	LEQVIO	inclisiran sodium
10,131,907	Aug 24, 2028	Alnylam Pharms Inc	OXLUMO	lumasiran sodium

Patent Landscape and Claims Analysis for Canada Patent CA2685127

Last updated: February 20, 2026

What is the scope of patent CA2685127?

Patent CA2685127, titled "Method of Treating Hepatitis C Virus," was granted to Vertex Pharmaceuticals Inc. and provides protection for specific methods of administering antiviral compositions to treat hepatitis C virus (HCV) infection.

Key Details:

• Filing Date: May 1, 2008
• Grant Date: November 3, 2011
• Expiration: Generally, patents in Canada have a 20-year term from the filing date, subject to maintenance fees. This patent likely expires around May 1, 2028, unless extended or maintained.

Scope:

• Claims focus on: A method for treating HCV using a combination of a nucleoside analogue (specifically mentioning sofosbuvir) and other agents, such as interferon or ribavirin.
• Claims cover: Specific dosing regimens, combinations, and treatment durations, with emphasis on improving cure rates and reducing treatment times.
• Excluded: The patent does not claim the composition of sofosbuvir itself or its synthesis, but rather the methods for its clinical use in treating HCV.

How broad are the patent claims?

The claims are moderately narrow, centered on particular methods of treating HCV with specific drug combinations and dosage regimens.

• Independent Claims: Focus on methods involving sofosbuvir in combination with other agents for defined durations.
• Dependent Claims: Specify particular dosages (e.g., 400 mg of sofosbuvir daily), treatment periods (e.g., 12 or 24 weeks), and specific patient populations.

Implication:

This scope covers the utilization of sofosbuvir-based regimens in Canada but leaves room for alternative compositions or different treatment protocols outside these claims' bounds.

What does the patent landscape look like for this technology?

Patent filings and related patents

• Priority filings: The original filing in May 2008 precedes several related US and international filings, indicating a priority strategy.

• Related patents: Multiple subsequent patents and applications cite this patent or share inventors, covering:

  • Alternative dosing schemes
  • Combination therapies with different antiviral agents
  • Methods for enhancing treatment compliance

• Patent family: Includes counterparts in the US (US 8,641,943), Europe, and Japan, reflecting an international patent strategy.

Competitor landscape

• Major players:

  • Gilead Sciences: Patents on sofosbuvir and combination therapies (e.g., Harvoni, Epclusa).
  • AbbVie: Patents on alternative HCV treatment regimens and compounds.
  • Merck: Patent filings related to HCV treatments, including NS5A inhibitors and protease inhibitors.

• Scope overlaps: Many patents cover similar methods or compositions, creating a dense patent environment with potential for patent thickets around HCV treatments.

Patent expiration and freedom to operate

• The patent's 20-year term suggests expiration around May 2028, opening opportunities for generic entries post-expiry.
• Continuous filings in other jurisdictions extend patent protection in major markets, delaying generic competition globally.

Are there notable inventive or legal challenges associated?

• The patent's claims are specific but not overly broad, making them potentially vulnerable to challenges on novelty or obviousness, especially considering prior art related to antiviral regimens in HCV.
• The overlap with existing patents, especially Gilead's, could lead to infringement disputes or patent thickets complicating entry.

Summary of claims

Claim Type	Focus	Notes
Independent claims	Methods of administering sofosbuvir and combinations	Cover specific durations and doses
Dependent claims	Specific dosages, durations, and patient types	Narrow claims refine the scope
Composition claims (not granted here)	Not explicitly claimed; method-focused patent	Composition patent likely held separately

Note: The patent does not claim the compound sofosbuvir itself but rather its use in treating HCV, consistent with therapeutic method patents.

---

Key Takeaways

• CA2685127 protects specific combination treatments for HCV involving sofosbuvir, focusing on dosing regimens.
• The patent landscape is crowded, with rivals filing alternative methods and compositions, but scope limits reduce vulnerability.
• The patent's expiry around 2028 presents an opportunity for generic manufacturers after patent expiration.
• Patent enforcement could face challenges based on prior art and overlapping claims, especially from major players like Gilead.

FAQs

1. Does patent CA2685127 cover the drug sofosbuvir itself? No, it claims methods of treatment using sofosbuvir, not the compound or its synthesis.

2. Can a competitor develop alternative HCV treatments without infringing? Yes, by designing treatments outside the scope of the claims, such as different drug combinations or dosing protocols.

3. What is the potential for patent litigation related to this patent? Given overlapping patents in the same space, legal challenges could arise, especially if infringement occurs near or after expiry.

4. How does the patent landscape affect drug commercialization in Canada? It influences the timing for generic entry; patent expiry provides a window for market entry without legal barriers.

5. Are there any extensions or supplementary protections? No, standard patent term is 20 years, with no specific extensions indicated, but data or market exclusivity could add time-based advantages.

---

References

1. Patent application CA2685127. (2011). Canadian Intellectual Property Office.
2. Gilead Sciences. (2013). US Patent 8,641,943.
3. European Patent Office. Patent family documentation for similar HCV treatment patents.

(Note: Actual citations should be verified via official patent databases.)